New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Bolt Biotherapeutics, Inc. (BOLT) vs Citius Pharmaceuticals, Inc. (CTXR)
- Bolt Biotherapeutics, Inc. BOLT 4.91 −2.96%
- Citius Pharmaceuticals, Inc. CTXR 0.51 +2.00%
Bolt Biotherapeutics, Inc. and Citius Pharmaceuticals, Inc. are both Biotechnology companies. Bolt Biotherapeutics, Inc. and Citius Pharmaceuticals, Inc. are of similar size ($13.7M and $13.2M). Citius Pharmaceuticals, Inc. has the higher net margin (0.00% vs −611.5%) and the higher return on invested capital (−58.7% vs −154.8%). Across the 13 metrics below, Citius Pharmaceuticals, Inc. leads on 9 and Bolt Biotherapeutics, Inc. on 4.
Valuation
Profitability
| Metric | BOLT | CTXR | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | — | 70.18% |
| Operating margin | (654.53%) | 0.00% | 0.00% |
| Net margin | (611.47%) | 0.00% | 0.00% |
| Free cash flow margin | (655.72%) | 0.00% | 0.00% |
| Return on equity | (127.96%) | (64.51%) | (51.58%) |
| Return on assets | (51.70%) | (34.29%) | (45.91%) |
| Return on invested capital | (154.77%) | (58.74%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack